Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.76 |
| ▸ | ABL1 | P00519 | 13/20 | 0.76 |
| ▸ | HCK | P08631 | 5/20 | 0.76 |
| ▸ | EGFR | P00533 | 3/20 | 0.75 |
| ▸ | LCK | P06239 | 2/20 | 0.75 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.75 |
| ▸ | CSK | P41240 | 2/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.68 |
| ▸ | MTOR | P42345 | 1/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.68 |
| ▸ | PRKDC | P78527 | 1/20 | 0.68 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17963678 | 0.87 | SRC (0.85) | SRCABL1HCKEGFRLCK | |
| SCHEMBL12435987 | 0.87 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL17963667 | 0.87 | SRC (0.62) | SRCABL1HCKEGFRLCK | |
| SCHEMBL12437089 | 0.86 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL12437035 | 0.85 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL29389670 | 0.85 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL29390823 | 0.85 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL14574681 | 0.85 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL12436124 | 0.84 | SRC (1.00) | SRCABL1HCKEGFRLCK | |
| SCHEMBL29390313 | 0.84 | SRC (1.00) | SRCABL1HCKEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | claimed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | claimed |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | claimed |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | claimed |
| WO-2016123151-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | claimed |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2020-04-28 | — | — | US | disclosed |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | UNIVERSITY OF WASHINGTON (US) | 2019-07-16 | — | — | US | disclosed |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-09-27 | — | — | US | disclosed |
| EP-3250290-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | University of Washington (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016123152-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIVERSITY OF WASHINGTON (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273537-A1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS, CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | PNCK, TXK, CAMKK1 | SRC 171/4885ABL1 1586/4885HCK 22/4885 |
| US-10632122-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, TXK, CAMKK1 | SRC 171/4885ABL1 1586/4885HCK 22/4885 |
| US-20180271871-A1 | BUMPED KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | CHEK2, CHEK1, DCK | SRC 76/4885ABL1 182/4885HCK 203/4885 |
| US-10350211-B2 | Bumped kinase inhibitor compositions and methods for treating cancer | CHEK2, CHEK1, DCK | SRC 76/4885ABL1 182/4885HCK 203/4885 |
| US-10307425-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases | PNCK, CAMKK1, CILK1 | SRC 177/4885ABL1 1558/4885HCK 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.